Disc Medicine’s stock is traded on the Nasdaq Global Market under the symbol “IRON”. The Company went public via a merger with Gemini Therapeutics, Inc. (GMTX) on December 29, 2022.
Disc Medicine’s fiscal year-end is December 31st.
Disc Medicine’s transfer agent is:
Broadridge Financial Solutions, Inc
www.broadridge.com
51 Mercedes Way Edgewood, NY 11717
Phone: (215)-553-5417
Disc Medicine’s legal counsel is Goodwin Procter LLP located in Boston, MA.
Disc Medicine’s independent auditor is Ernst & Young located in Boston, MA.
Disc Medicine’s press release archives can be viewed here.
Disc Medicine SEC filings can be found on www.sec.gov and are also available here.
Our stockholders’ meeting will be held annually. Instructions on how to attend will be delivered to all stockholders.
Please email ir@discmedicine.com for assistance.
To find out more about us, visit our webpage at www.discmedicine.com or sign up here to receive email alerts .